The Golgi apparatus is best known as the processing and dispatch center of the secretory pathway. Proteins manufactured in the endoplasmic reticulum pass through its stacked membrane cisternae, where they are chemically modified, most notably through glycosylation, the attachment of sugar chains, and then sorted to their correct destinations, whether the plasma membrane, secretory vesicles, or lysosomes. The organelle also manufactures key lipids such as sphingomyelin and glycosphingolipids, participates in autophagosome formation, and runs its own quality-control degradation pathways. In other words, the Golgi sits at the crossroads of protein and lipid homeostasis, which is precisely why its failure could ripple through nearly every cellular process implicated in neurodegeneration.

That failure is not hypothetical. Postmortem studies of Alzheimer’s brains have long revealed fragmented, atrophied Golgi structures in affected neurons. More strikingly, when researchers expressed the amyloid precursor protein Swedish mutant in cells, the Golgi fragmented, and restoring Golgi architecture by expressing the structural proteins GRASP65 and GRASP55 dramatically reduced amyloid-beta production. In induced pluripotent stem cell-derived neurons from patients with sporadic Alzheimer’s disease, the fragmented Golgi phenotype persisted and, crucially, appeared before amyloid and tau pathology developed, suggesting that Golgi breakdown may be one of the earliest cellular events in the disease rather than a late consequence of it.

The strongest new argument for the Golgi’s relevance comes from large-scale human data. When the authors surveyed genetic studies, a striking pattern emerged: multiple independent analyses keep nominating Golgi-related genes as Alzheimer’s risk factors. An RNA-sequencing analysis found that Golgi-related gene ontology terms were elevated both in patients and in people with high polygenic risk scores for the disease, particularly in the temporal cortex. An X-chromosome-wide association study identified SLC9A7, a sodium/proton exchanger concentrated in the trans-Golgi network that maintains the organelle’s acidity, as the only genome-wide significant risk locus. Because Golgi luminal pH governs protein modification, glycosylation, and trafficking, its disruption could derail amyloid precursor protein processing among many other consequences.

Other risk genes reinforce the same theme. SORL1 and SORCS1, both well-established genetic risk factors, encode sortilin-family receptors that shepherd the amyloid precursor protein back to the trans-Golgi network, keeping it away from the endosomes where amyloidogenic cleavage predominates. Adaptor protein 4 complex genes AP4M1 and AP4E1, flagged by enhancer mapping of genome-wide association loci, regulate the precursor protein’s delivery to endosomes. A protective variant in NSF, a gene essential for Golgi reassembly and vesicle fusion, was identified in whole-exome sequencing of patients lacking the ApoE4 allele, hinting that Golgi integrity itself may confer resilience. Machine learning analysis of European GWAS data proposed COG7, a subunit of the complex that maintains Golgi structure and glycosylation, as a new risk gene, and multiancestry proteomic analyses independently nominated COG7, the trans-Golgi metalloprotease CPD, and the retrograde trafficking proteins SNX1, SNX32, and STX6 as candidate causal proteins.

Proteomics adds a second layer of evidence. A landmark 2022 study of more than 500 human brain samples found that Golgi and protein transport module signatures were reduced in asymptomatic Alzheimer’s brains and diminished further in symptomatic cases, correlating with cognitive scores. Perhaps most intriguingly, the extracellular matrix protein repertoire, the matrisome, showed the most prominent proteomic changes in the disease that were invisible at the RNA level, implying that post-translational modifications are the real driver. Since matrix proteins such as proteoglycans and collagen are extensively processed and glycosylated within the Golgi before secretion, Golgi dysfunction offers a mechanistically coherent explanation for this transcriptome-proteome discordance, and matrisome proteins are known to colocalize with amyloid plaques.

A 2024 glycomics study sharpened the picture further by mapping the N-glycan landscape of Alzheimer’s brains. The most altered sugar structures, sialylated and highly branched forms, are built inside the Golgi, and the affected glycoproteins clustered at synapses and the cell surface. Glycoform signatures tied to disease status involved L1CAM and NPTX1, markers of synaptic plasticity and synaptic loss, as well as ATP1B1, a subunit of the sodium-potassium pump essential for neural signaling. Expression of several Golgi-resident glycosylation enzymes, including MAN2A1, MGAT1, and members of the B3GALT, B4GALT, ST6GAL, and ST8SIA families, was altered across multiple brain regions, consistent with a systematic breakdown of Golgi-dependent protein modification that could directly undermine synapses.

Lipid biology supplies a third pillar. The Golgi is the primary site of ceramide processing through glucosylceramide synthase, whose levels fall in Alzheimer’s brains in correlation with ceramide accumulation, a lipid that promotes amyloid-beta production, oxidative stress, and neuronal death. The Golgi-localized enzyme neutral sphingomyelinase 2 drives the secretion of extracellular vesicles that can spread pathological tau between cells; inhibiting it reduced tau propagation and neurodegeneration in mouse models, and neuronal deletion of the gene reduced amyloid-beta production. Meanwhile, the oxysterol-binding protein OSBP1, which exchanges cholesterol and PI4P between the trans-Golgi network and the endoplasmic reticulum at membrane contact sites, regulates cholesterol distribution, mitochondrial fission, and retrograde trafficking, and its knockdown increased amyloidogenic processing of the amyloid precursor protein, linking Golgi-managed cholesterol homeostasis directly to plaque biology.

The authors synthesize these threads into four candidate pathogenic mechanisms. First, Golgi fragmentation may disrupt the normal segregation of the amyloid precursor protein and its processing enzymes, increasing their contact and boosting amyloid-beta generation, possibly even within the Golgi itself. Second, impaired trafficking between the Golgi and the endolysosomal system would trap the precursor protein in endosomes while starving lysosomes of properly sorted enzymes, simultaneously raising amyloid production and lowering its clearance. Third, defective glycosylation would alter countless proteins, including the amyloid precursor protein itself, whose O-glycosylation influences its trafficking and cleavage. Fourth, lipid dyshomeostasis would feed back on Golgi membrane integrity, creating a self-reinforcing vicious cycle that also damages mitochondria and the endoplasmic reticulum. Upstream triggers, including aging, DNA damage, oxidative stress, and neuronal hyperexcitability, as well as amyloid-beta and tau themselves, can all induce Golgi fragmentation, closing the loop.

Therapeutically, the possibilities are still largely conceptual but tantalizing. Restoring Golgi structural integrity, for example through nonphosphorylatable GRASP55/65 variants, could in principle ameliorate multiple disease processes at once. More targeted options include nSMase2 inhibitors, which have already shown benefits in Alzheimer’s mouse models; overexpression of SORL1, which redirects the amyloid precursor protein to the Golgi and lowers amyloid-beta output; and reinforcement of glycosylation or lipid balance through COG7, glucosylceramide synthase, or OSBP1. The authors are candid about the caveats: causality between Golgi dysfunction and Alzheimer’s pathogenesis has not been rigorously established, most evidence comes from familial disease models rather than the sporadic form that accounts for roughly 90 percent of cases, and because the Golgi handles so much cellular traffic, interventions could carry pleiotropic side effects. Still, with anti-amyloid antibodies delivering only modest clinical benefit, the review makes a compelling case that keeping this cellular post office running smoothly may be one of the most underexplored strategies for halting the disease, and that the humble Golgi apparatus deserves a central seat at the Alzheimer’s research table.

Subject of Research: The role of Golgi apparatus dysfunction in Alzheimer's disease pathogenesis and therapy

Article Title: Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets

Article References: Song, J., Lee, S.-J., & Mook-Jung, I. (2026). Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01851-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01851-8

Keywords: Alzheimer's disease, Golgi apparatus, amyloid-beta, tau, glycosylation, lipid metabolism, SORL1, trans-Golgi network, multiomics, neurodegeneration, endolysosomal trafficking, therapeutic targets

The protein in question is PIK3C3, better known in the research world as VPS34. First identified decades ago in yeast cells as a traffic controller that sorts and shuttles proteins to and from the cell membrane, VPS34 later earned fame for a second role: autophagy, the recycling program by which cells break down their own components to survive stress. Because fast-growing tumors depend heavily on autophagy to weather nutrient shortages and to dispose of substances that might otherwise alert the immune system, VPS34 has long been an attractive target for cancer researchers. The new study, published in the journal Autophagy, reveals that its importance extends beyond keeping tumor cells alive — it also determines how easily those cells can be spotted by the body’s defenses.

The key molecule in this story is GD2, a fatty substance with a small sugar chain that decorates the surface of neuroblastoma cells. Anti-GD2 immunotherapy works through lab-made monoclonal antibodies, such as dinutuximab and naxitamab, which are engineered to latch onto GD2 and flag the tumor for destruction by the patient’s own immune cells. The Penn State team, led by corresponding author Hong-Gang Wang, Lois High Berstler Professor of Pediatrics, found that inhibiting VPS34 raised the amount of GD2 displayed on the tumor cell surface. More GD2 means more docking sites for the antibodies — in Wang’s words, the tumor cells become more visible and give the antibodies more to latch onto.

The experimental evidence came from a series of careful measurements. When the researchers blocked VPS34 in cell cultures, they used flow cytometry, a technique that tags specific molecules with fluorescent markers and passes individual cells through a laser to quantify them. The treated cells glowed brighter, indicating elevated surface GD2. Intriguingly, blocking VPS34 increased the total amount of GD2 inside the cells, but the surface pool rose disproportionately, shifting the balance toward the outer membrane where antibodies can reach it. The most exciting finding, Wang noted, was that VPS34 inhibition increased GD2 presentation, making the tumor more visible to the antibody.

Not every result followed the expected script. Because the team’s hypothesis was rooted in autophagy — the idea that starving tumor cells of their recycling machinery would weaken them — they anticipated that the effect would depend on nutrient stress. Yet when VPS34 was blocked in lab cultures, where oxygen and nutrients are plentiful and cells do not rely heavily on autophagy, the tumor cells died anyway, independent of any immunotherapy. This suggested that VPS34’s other, older function — endolysosomal trafficking, the routing of material to different cellular destinations including the membrane — was also at play.

To disentangle the two roles, the researchers ran control experiments targeting ATG14, a protein that partners with VPS34 specifically for autophagy while leaving VPS34’s trafficking duties untouched. Blocking ATG14 produced a dramatically reduced effect on GD2, pointing to endolysosomal trafficking as a central mechanism behind the increased surface display. In mouse models, meanwhile, tumors grew poorly when the team targeted ATG14 and other autophagy genes. The two functions of VPS34, Wang concluded, likely work in tandem to help neuroblastoma cells survive — which means disrupting them strikes the cancer from multiple directions at once.

The therapeutic payoff emerged when VPS34 inhibition was paired with monoclonal antibodies in both cells and mice. The combination outperformed either approach alone. According to first author Jiawen Zhang, a biomedical sciences doctoral student, the brighter cancer cells with elevated GD2 became easier targets not only for the antibodies but for the natural killer cells that bind to them. Once engaged, these NK cells release perforin, a protein that punches holes in the cancer cell membrane, and granzymes, enzymes that pass through those holes and trigger cell death. In both experimental systems, tumor growth was significantly suppressed, and in mice, survival improved. Combining the two therapies, Zhang said, gave better results.

The implications may reach beyond neuroblastoma. High levels of GD2 also appear on melanoma and osteosarcoma cells, but anti-GD2 immunotherapy is currently approved as standard care only for neuroblastoma. Wang suggested that the strategy could potentially be tested in other tumor types that express high GD2 on their surfaces, broadening the relevance of the work well past the pediatric population in which it was conceived. The concept — making tumors more conspicuous by manipulating their internal logistics — could in principle complement antibody-based therapies across several cancers.

Significant hurdles remain before patients benefit. VPS34 inhibitors are still largely confined to pre-clinical studies, and off-target effects frequently complicate experiments in living subjects. What is missing, Wang emphasized, is a clinical-grade VPS34 drug. He expressed hope that the findings will encourage the research community to view VPS34 as an important target and accelerate drug discovery and testing efforts to complement anti-GD2 immunotherapy. The study, he said, provides the pre-clinical evidence and rationale that, once better VPS34 inhibitors are developed, combining them with anti-GD2 antibodies could become an important neuroblastoma treatment strategy.

The research was carried out by a broad Penn State team that included Longgui Chen, research technologist; Todd D. Schell, professor of cell and biological systems; Giselle Saulnier Sholler, Four Diamonds Endowed Chair for Pediatric Oncology Research; Vladimir Spiegelman, THON Chair for Pediatric Cancer Research; and Yoshinori Takahashi, associate professor of pediatrics and of cell and biological systems. Xiaoming Liu, who conducted the research as a doctoral student and has since graduated, also contributed. Funding came from the National Institutes of Health’s National Cancer Institute through awards R01CA222349, R21CA252748 and R01CA304343, along with the Lois High Berstler Research Endowment and Four Diamonds. For families facing high-risk neuroblastoma, the work offers a concrete biological rationale for a combination approach that could turn an elusive cancer into an open target — and a reminder that sometimes the most powerful way to defeat a tumor is simply to make it impossible for the immune system to ignore.

Subject of Research: VPS34 inhibition as a strategy to enhance anti-GD2 immunotherapy in pediatric neuroblastoma

Article Title: Making pediatric cancer more ‘visible’ boosts immunotherapy response

Article References: Making pediatric cancer more ‘visible’ boosts immunotherapy response. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuroblastoma, pediatric cancer, immunotherapy, VPS34, GD2, monoclonal antibodies, autophagy, endolysosomal trafficking, natural killer cells, dinutuximab, naxitamab, preclinical study

The strongest case for this idea comes from genetics. Over the past twenty years, researchers hunting for genes that cause or raise the risk of neurodegenerative disorders have repeatedly landed on the endolysosomal system, the network of vesicles and organelles that ferries cargo to lysosomes for destruction. In Parkinson disease, the evidence is particularly compelling. A substantial proportion of genes linked to the condition encode proteins that are essential for lysosomal health, and the two most common genetic causes of Parkinson disease, mutations in GBA1 and LRRK2, both converge on lysosomal biology. Remarkably, both of these pathways are now being targeted in clinical trials, marking one of the first times that fundamental cell biology has been translated so directly into therapeutic strategies for a neurodegenerative illness.

The GBA1 story illustrates how a single gene can illuminate an entire disease mechanism. GBA1 encodes glucocerebrosidase, a lysosomal enzyme that breaks down fatty substances called glucosylceramides. People who carry one mutated copy of the gene are at markedly elevated risk of developing Parkinson disease, and studies have shown that reduced glucocerebrosidase activity in the substantia nigra, the brain region that degenerates in Parkinson disease, is associated with increased levels of alpha-synuclein, the protein that clumps into the Lewy bodies that define the disorder. Work from the Krainc laboratory and others has revealed a bidirectional loop: deficient glucocerebrosidase impairs the degradation of alpha-synuclein, while accumulating alpha-synuclein in turn blocks the delivery of fresh glucocerebrosidase to lysosomes, creating a vicious cycle of worsening protein aggregation and deepening lysosomal failure.

LRRK2, the other major Parkinson gene, tells a complementary story. This large kinase enzyme phosphorylates a family of Rab GTPases that regulate membrane trafficking throughout the cell. When lysosomes are damaged, LRRK2 is recruited to their surface through pathways involving the CASM machinery and GABARAP proteins, where it helps coordinate membrane repair and the removal of damaged lysosomal material. Pathogenic LRRK2 mutations boost kinase activity, producing enlarged lysosomes with reduced degradative capacity and impairing the clearance of alpha-synuclein. Because LRRK2 is also active in immune cells, its dysfunction extends to microglia, the brain’s resident immune cells, linking lysosomal failure to the neuroinflammation that accompanies neurodegeneration. LRRK2 kinase inhibitors, including the molecule BIIB122, have already been tested in patients, and a broad initiative called the LRRK2 investigative therapeutics exchange is working to overcome the remaining obstacles to translating this biology into disease-modifying therapies.

Beyond these headline genes, the review catalogues an expanding roster of lysosomal proteins implicated in Parkinson disease. Mutations in VPS35, a core component of the retromer complex that sorts cargo through endosomes, cause familial Parkinson disease and disrupt the retrieval of the chaperone-mediated autophagy receptor LAMP2A, which neurons use to deliver alpha-synuclein to lysosomes for destruction. ATP13A2, a lysosomal transporter whose loss causes an early-onset form of parkinsonism, exports polyamines from the lysosome, and its deficiency triggers lysosomal dysfunction and alpha-synuclein accumulation. The lysosomal ion channel TMEM175, identified through genome-wide association studies as a risk factor, regulates the proton balance that keeps lysosomes acidic enough for their digestive enzymes to function. Even the recently characterized Commander complex has emerged as a regulator of lysosomal function and Parkinson disease risk. Each of these discoveries reinforces the same message: many independent genetic insults funnel into a single vulnerable pathway.

In Alzheimer disease, the lysosomal connection takes a somewhat different form, centered on the endocytic trafficking machinery. Enlarged endosomes packed with amyloid-beta are among the earliest pathological changes detectable in neurons of people with Alzheimer disease, appearing before amyloid plaques form. The strongest genetic link is SORL1, which encodes the receptor SORLA, a key regulator of cargo trafficking through the endolysosomal system, including trafficking of the amyloid precursor protein. Loss-of-function variants in SORL1 substantially increase Alzheimer risk, and depletion of SORLA in human neurons impairs endosomal traffic even independently of amyloidogenic processing. Other risk genes, including BIN1, PICALM and CD2AP, all participate in endocytosis and endosomal sorting, and presenilin mutations that cause familial Alzheimer disease disrupt lysosomal acidification and autophagy, although the precise role of presenilins in this process remains debated.

The lipid-carrying protein APOE adds another layer to the Alzheimer picture. The APOE4 allele, the strongest common genetic risk factor for late-onset disease, promotes the accumulation of cholesterol in lysosomes of astrocytes, impairs mitochondrial function and dampens autophagy through multiple mechanisms, including direct binding of ApoE4 to gene regulatory elements that control autophagy genes. Meanwhile, TREM2, a receptor on microglia that depends on lysosomal processing for its function, shapes how immune cells respond to amyloid plaques, although a recent clinical trial targeting TREM2 failed, underscoring how much remains to be learned about translating lysosomal biology into treatments.

Frontotemporal dementia and amyotrophic lateral sclerosis, two clinically distinct disorders with heavily overlapping genetics, supply perhaps the most direct evidence that autophagy, the cellular self-eating process that delivers cargo to lysosomes, is essential for neuronal survival. Multiple ALS and FTD genes encode proteins that regulate autophagy at different steps: TBK1 and OPTN coordinate the selective removal of damaged mitochondria; VCP and UBQLN2 participate in extracting ubiquitinated proteins for degradation; SQSTM1, also known as p62, serves as a cargo receptor that tags aggregates for autophagic clearance; and C9ORF72, the most common genetic cause of both diseases, forms a complex that regulates Rab GTPases and mTORC1 signaling at the lysosome. Mutations in CHMP2B, part of the ESCRT-III machinery that repairs ruptured lysosomal membranes, cause a distinctive form of frontotemporal dementia characterized by lysosomal storage pathology, and recent work shows that the ALS-linked proteins annexin A11 and CHMP2B act sequentially in membrane repair.

Progranulin, encoded by the GRN gene, has become a focal point for therapeutic development in frontotemporal dementia. Haploinsufficiency, meaning that carriers of a single mutated GRN copy produce only half the normal amount of the protein, causes familial FTD and produces features resembling neuronal ceroid lipofuscinosis, a classic lysosomal storage disease. Progranulin supports lysosomal homeostasis through multiple mechanisms: it promotes lysosomal acidification, acts as a chaperone for the enzyme cathepsin D, facilitates the processing of prosaposin into saposins that activate lipid-degrading enzymes, and supports glucocerebrosidase activity. The risk gene TMEM106B, which regulates lysosomal size, motility and stress responses, modifies disease penetrance in GRN mutation carriers, and strikingly, TMEM106B itself was recently discovered to form amyloid fibrils in aged brains across multiple neurodegenerative diseases. Progranulin augmentation strategies, including an antibody called latozinemab that raises progranulin levels and AAV gene therapy, are already in clinical trials, with interim results reported for the gene therapy approach.

What emerges from this synthesis is a view of neurodegeneration as, at its core, a failure of cellular housekeeping that unfolds over decades. Neurons are uniquely vulnerable because they live as long as the organism, rely heavily on long-range transport of lysosomes along axons, and generate toxic metabolic byproducts such as oxidized dopamine that further damage lysosomes. The convergence of genetic evidence from four major disease families onto the endolysosomal system suggests that therapies aimed at restoring lysosomal health, whether by enhancing enzyme activity, improving acidification, boosting autophagic flux or repairing damaged lysosomal membranes, could offer benefits that span diagnostic boundaries. With GBA1 and LRRK2 trials underway in Parkinson disease, progranulin augmentation advancing in frontotemporal dementia and lysosome-targeting small molecules in preclinical development, the humble lysosome has moved from the margins of neuroscience to the center of the search for disease-modifying treatments.

Subject of Research: Lysosomal dysfunction as a mechanism of neurodegenerative disease

Article Title: Lysosomal dysfunction in neurodegenerative disease

Article References: Brooker, S. M., Coukos, R., & Krainc, D. (2026). Lysosomal dysfunction in neurodegenerative disease. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01262-3

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01262-3

Keywords: lysosome, neurodegeneration, Parkinson disease, Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, GBA1, LRRK2, autophagy, progranulin, alpha-synuclein, endolysosomal trafficking